scholarly journals Evaluation of an Indirect Immunofluorescence Assay for Detection of Immunoglobulin M (IgM) and IgG Antibodies against Yellow Fever Virus

2007 ◽  
Vol 15 (2) ◽  
pp. 177-181 ◽  
Author(s):  
Matthias Niedrig ◽  
Oliver Kürsteiner ◽  
Christian Herzog ◽  
Karen Sonnenberg
Keyword(s):  
Yellow Fever ◽  
Indirect Immunofluorescence ◽  
Yellow Fever Virus ◽  
Immunofluorescence Assay ◽  
Encephalitis Virus ◽  
Immunoglobulin M ◽  
Fever Virus ◽  
Indirect Immunofluorescence Assay ◽  
Igg Antibodies ◽  
Igm Antibodies

ABSTRACT The first commercial indirect immunofluorescence assay (IFA) using Euroimmun Biochip technology was evaluated for the serodiagnosis of immunoglobulin G (IgG) and IgM antibodies against yellow fever virus (YFV) and was compared with the plaque reduction neutralization test (PRNT), which is currently the gold standard test for YFV. An overall correlation between the tests of 98.7% was established based on the analysis of 150 sera from individuals after vaccination with the 17D yellow fever vaccine. The sensitivity and specificity, calculated using the 150 sera from vaccinees and 150 sera from healthy blood donors, were 95% and 95%, respectively, for the IgG IFA and 94% and 97% for the IgM IFA. Antibody titers found in the PRNT correlated poorly with the IgM and IgG titers detected by IFA. The analysis of preexisting heterologous flaviviral immunity revealed the presence of antibodies reactive with YFV, tick-borne encephalitis virus, West Nile virus, Japanese encephalitis virus, and dengue virus serotypes 1 to 4 in 20 out of the 150 vaccinees. The indirect IFA showed that nine of these individuals with previous flaviviral exposure who received 17D vaccine failed to produce detectable IgM antibodies. Despite this preexisting immunity, all vaccinees developed protective immunity as detected by PRNT and anti-YFV IgG antibodies as detected by IFA. The high specificity and sensitivity of the IFA make it a useful tool for rapid diagnosis of yellow fever during outbreaks, for epidemiological studies, and for serosurveillance after vaccination.

Thiosemicarbazones and Phthalyl-Thiazoles compounds exert antiviral activity against yellow fever virus and Saint Louis encephalitis virus

2017 ◽  
Vol 87 ◽  
pp. 381-387 ◽  
Author(s):  
Carolina Colombelli Pacca ◽  
Rafael Elias Marques ◽  
José Wanderlan P. Espindola ◽  
Gevânio B.O.Oliveira Filho ◽  
Ana Cristina Lima Leite ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Yellow Fever ◽  
Yellow Fever Virus ◽  
Encephalitis Virus ◽  
Fever Virus ◽  
Saint Louis ◽  
Saint Louis Encephalitis

scholarly journals Experience of application of IgY-technology for laboratory diagnostics of viral infections

2020 ◽  
Vol 65 (1) ◽  
pp. 21-26 ◽  
Author(s):  
A. P. Ivanov ◽  
T. D. Klebleeva ◽  
O. E. Ivanova
Keyword(s):  
Yellow Fever ◽  
Viral Infections ◽  
Yellow Fever Virus ◽  
Laboratory Diagnosis ◽  
Encephalitis Virus ◽  
Fever Virus ◽  
Laboratory Animals ◽  
Tick Borne Encephalitis ◽  
Tick Borne Encephalitis Virus

Introduction. The well-known advantages of class Y antibodies (IgY) from egg yolks of immunized hens in comparison with class G antibodies (IgG) of laboratory animals traditionally used in laboratory diagnosis of infectious diseases determine the stable interest of researchers in using IgY for these purposes (IgY technology) . Over the past 20 years, the obvious benefits of IgY technology have been demonstrated for a number of viral and bacterial infections. Goals and objectives. Construction of ELISA systems based on specific IgY for laboratory diagnosis of infections caused by tick-borne encephalitis virus, yellow fever virus, poliovirus.Material and methods. Obtaining yolk preparations of immunized chickens, obtaining highly purified IgY preparations (salting out, affinity chromatography), constructing ELISA systems for determining virus-specific antigens, testing the parameters of ELISA systems.Results and discussion. For the first time in laboratory practice, ELISA systems based on the use of specific polyclonal IgY were designed for laboratory diagnosis of topical human viral infections caused by flaviviruses and enteroviruses: determination of antigens of tick-borne encephalitis virus, yellow fever virus, 3 types of poliovirus. It was experimentally shown that these ELISA systems have high sensitivity and specificity, which allows them to be used for the semiquantitative and quantitative determination of antigens of these viruses in various materials (infected cell cultures, vaccines, etc.).Conclusion. The ELISA systems developed on the basis of specific IgY for determination of viral antigens can be effectively used for laboratory diagnosis of a number of viral infections, for the validation and control of vaccine preparations.

scholarly journals Detection of Anti-Yellow Fever Virus Immunoglobulin M Antibodies at 3–4 Years Following Yellow Fever Vaccination

2012 ◽  
Vol 87 (6) ◽  
pp. 1112-1115 ◽  
Author(s):  
Katherine B. Gibney ◽  
Olga I. Kosoy ◽  
Marc Fischer ◽  
Srilatha Edupuganti ◽  
Robert S. Lanciotti ◽  
...  
Keyword(s):  
Yellow Fever ◽  
Yellow Fever Virus ◽  
Immunoglobulin M ◽  
Fever Virus ◽  
Yellow Fever Vaccination

scholarly journals Molecular Basis for Attenuation of Neurovirulence of a Yellow Fever Virus/Japanese Encephalitis Virus Chimera Vaccine (ChimeriVax-JE)

2001 ◽  
Vol 75 (2) ◽  
pp. 934-942 ◽  
Author(s):  
Juan Arroyo ◽  
Farshad Guirakhoo ◽  
Sabine Fenner ◽  
Zhen-Xi Zhang ◽  
Thomas P. Monath ◽  
...  
Keyword(s):  
Amino Acid ◽  
Japanese Encephalitis Virus ◽  
Yellow Fever ◽  
Japanese Encephalitis ◽  
Yellow Fever Virus ◽  
Encephalitis Virus ◽  
Fever Virus ◽  
Single Amino Acid ◽  
E Protein ◽  
Viral Vaccine

ABSTRACT A yellow fever virus (YFV)/Japanese encephalitis virus (JEV) chimera in which the structural proteins prM and E of YFV 17D are replaced with those of the JEV SA14-14-2 vaccine strain is under evaluation as a candidate vaccine against Japanese encephalitis. The chimera (YFV/JEV SA14-14-2, or ChimeriVax-JE) is less neurovirulent than is YFV 17D vaccine in mouse and nonhuman primate models (F. Guirakhoo et al., Virology 257:363–372, 1999; T. P. Monath et al., Vaccine 17:1869–1882, 1999). Attenuation depends on the presence of the JEV SA14-14-2 E protein, as shown by the high neurovirulence of an analogous YFV/JEV Nakayama chimera derived from the wild JEV Nakayama strain (T. J. Chambers, A. Nestorowicz, P. W. Mason, and C. M. Rice, J. Virol. 73:3095–3101, 1999). Ten amino acid differences exist between the E proteins of ChimeriVax-JE and the YFV/JEV Nakayama virus, four of which are predicted to be neurovirulence determinants based on various sequence comparisons. To identify residues that are involved in attenuation, a series of intratypic YFV/JEV chimeras containing either single or multiple amino acid substitutions were engineered and tested for mouse neurovirulence. Reversions in at least three distinct clusters were required to restore the neurovirulence typical of the YFV/JEV Nakayama virus. Different combinations of cluster-specific reversions could confer neurovirulence; however, residue 138 of the E protein (E138) exhibited a dominant effect. No single amino acid reversion produced a phenotype significantly different from that of the ChimeriVax-JE parent. Together with the known genetic stability of the virus during prolonged cell culture and mouse brain passage, these findings support the candidacy of this experimental vaccine as a novel live-attenuated viral vaccine against Japanese encephalitis.

Sign in / Sign up

Export Citation Format

Share Document